– USA, MN – Humanetics Corporation, a clinical-stage specialty pharmaceutical company pioneering radiation countermeasures, adjunctive oncology therapies, and pulmonary protective therapies for COVID-19, today announced the addition of Jake Nunn to its Board of Directors.
“We can’t overstate the significance of bringing Mr. Nunn onto our Board. He brings exceptional insights and experience from venture capital and institutional investors, focusing on business growth and maximizing shareholder value. We’re incredibly fortunate to be collaborating with him,” said CEO, Ron Zenk.
About Jake R. Nunn
Jake Nunn’s insights will be invaluable as Humanetics’s proprietary drug BIO 300 gains traction for its potential to mitigate the harmful effects of radiation exposure on warfighters, first responders, and healthy tissues in certain cancer patients, as well as improve outcomes for COVID-19 long haulers.
“I’m excited to join the Board of Humanetics,” said Jake Nunn. “After more than 25 years of experience in the Life Sciences industry, I’ve pivoted to work as an independent advisor precisely for the opportunity to engage with and support clinical-stage specialty pharma companies like Humanetics to help them position and prepare for their next phase of growth.”
Mr. Nunn has 25 years of experience in the life science industry as an investor, independent director, research analyst, and investment banker. He is currently an independent advisor to life science companies and a venture advisor at New Enterprise Associates, or NEA, where he was a partner from 2006-2018. He has served at the executive level of several companies that underwent successful acquisitions and has particular expertise in later-stage specialty pharmaceuticals. He received an MBA from the Stanford Graduate School of Business and a degree in Economics from Dartmouth College.
Mr. Nunn holds the Chartered Financial Analyst designation, is a member of the CFA Society of San Francisco, and recently completed the Stanford GSB Directors’ Consortium executive education program.
About Humanetics Corporation
Humanetics is a clinical-stage specialty pharmaceutical company engaged in the accelerated discovery, development, and commercialization of proprietary drugs in markets with urgent and unmet needs, with a focus on medical countermeasures to prevent harm caused by exposure to radiation, for protective use in cancer radiation therapy, and to guard against the long-term damaging effects of COVID-19.
For more information: https://www.humaneticscorp.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
